Astrazeneca Pharmaceuticals LP
Wilmington, DE
- UEI
- E5K2ZJ8CTJH4
- CAGE
- 36WK2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Alexion Pharmaceuticals Inc, ranks #67 in NAICS 325411
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- Medimmune LLC · Gaithersburg, MD PHXNKFPB76E7
-
- SAM.gov registration date
- Physical address
- 1800 Concord Pike, Wilmington, DE 19803, USA
- Website
- astrazeneca-us.com
- Founded
- 1999
- Employees
- 50K-100K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $500 |
| FY2025 | -$19,822 |
| FY2024 | $500 |
| FY2023 | -$12,975 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Logistics Agency | $500 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Other medical | Medical Supply Chain (DLA) | $500 | |
| Other medical | Medical Supply Chain (DLA) | $500 | |
| Other medical | Medical Supply Chain (DLA) | $500 | |
| Purchase of influenza vaccine supplies for nssc customers. | Indian Health Service | $0 | |
| Other medical | Medical Supply Chain (DLA) | $500 |
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Glaxosmithkline, LLC | Durham, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Pfizer Inc. | New York, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Sanofi Pasteur Inc. | Swiftwater, PA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Merck Sharp & Dohme LLC | Rahway, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Prasco, LLC | Mason, OH | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Astrazeneca Pharmaceuticals LP, a foreign-owned for-profit pharmaceutical manufacturer headquartered in Wilmington, Delaware, supplies vaccines, pharmaceutical preparations, and medical countermeasures to federal agencies as a prime contractor on full-and-open contracts with no set-aside designations. The company operates across 221 recent prime awards (100% of its federal footprint) valued at $17.45 billion in combined potential value, with $3.1 billion obligated to date.
Astrazeneca's federal capability portfolio centers on seasonal influenza vaccines (pediatric and adult formulations), prescription pharmaceuticals for veteran and federal employee populations, and medical supplies distributed through federal health agencies. Representative work includes a $75.52 million CDC Indefinite Delivery Contract for pediatric flu vaccines covering the 2022–2023 season (awarded January 5, 2022, through February 28, 2023); a $913.9 million single-award VA contract for acalabrutinib tablets (100 mg BTK inhibitor) serving the Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service (awarded June 24, 2024, through June 23, 2027, with four one-year options, second option exercised); and a $58.53 million CDC multiple-award contract for pediatric flu vaccines for the 2023–2024 season. Recent 2025 awards include a $32.01 million CDC pediatric flu vaccine contract and a $9.3 million CDC adult flu vaccine contract, both through February 28, 2027. Astrazeneca also received two National Institute on Drug Abuse cooperative agreements as research recipient for development of AZD4041/BPN-19302, a selective orexin-1 receptor antagonist for opioid use disorder treatment, in collaboration with Eolas Therapeutics and the NIH Blueprint Neurotherapeutics Network (awarded August 15, 2021; one agreement completed March 31, 2024, the second through February 28, 2025).
Customer concentration heavily favors the Department of Veterans Affairs Veterans Integrated Service Network 12, which anchors $11.86 billion (68% of combined potential value) across two awards, primarily the acalabrutinib contract. The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense holds $2.79 billion across five awards; the VA National Acquisition Center holds $1.66 billion across four awards; and CDC Pittsburgh holds $986.4 million across twenty awards. These five customers account for all tracked potential value. Award volume has remained modest and flat — five awards in 2021, six in 2022, two in 2023, six in 2024, and three in 2025 — with minimal near-term recompete exposure (one award of $500 completing in the next twenty-four months).
Astrazeneca's top parent vehicles are the Indefinite Delivery Contract SPE2D017D0002 (ten task orders, $5 thousand combined value) and several Federal Supply Schedules (V797P5274X, V797P5853N, V797P5343X combined). Award categories concentrate in Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (148 awards, primarily the vaccine supply work), Pharmaceutical Preparation Manufacturing (40 awards), and Medicinal and Botanical Manufacturing (11 awards), with corresponding PSC codes reflecting Drugs and Biologicals (45 awards) and Medical and Surgical Instruments, Equipment, and Supplies (154 awards).
The company's named subsidiary is Medimmune LLC, a for-profit organization that develops and manufactures vaccines and immunotherapeutics for federal health agencies. Astrazeneca competes on full-and-open, unrestricted procurements reflective of its large business status and does not participate in set-aside categories.
Quick answers
Is Astrazeneca Pharmaceuticals LP registered in SAM.gov?
Yes. Astrazeneca Pharmaceuticals LP's SAM.gov registration is active through August 18, 2027.
Which contract vehicles does Astrazeneca Pharmaceuticals LP hold?
Astrazeneca Pharmaceuticals LP holds a place on 1 federal contract vehicle: FSS-61-IB.
How does Astrazeneca Pharmaceuticals LP rank among federal contractors?
Astrazeneca Pharmaceuticals LP's parent company, Alexion Pharmaceuticals Inc, ranked #67 in NAICS 325411 in FY2025.
What is Astrazeneca Pharmaceuticals LP's most recent federal award?
Astrazeneca Pharmaceuticals LP's most recent federal contract award is Other medical (SPE2D026F0023), from Medical Supply Chain (DLA), on November 3, 2025.
On GovTribe
See Astrazeneca Pharmaceuticals LP's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors